SCHEMBL7239277

SCHEMBL7239277

C/C(=C/C(=O)O)c1ccc2ncccc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.58
HTT P42858 1/20 0.58
PLK1 P53350 1/20 0.58
DOT1L Q8TEK3 1/20 0.52
ALDH1A1 P00352 5/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
LMNA P02545 1/20 0.52
CYP3A4 P08684 2/20 0.49
BCAT1 P54687 1/20 0.48
RAB9A P51151 4/20 0.48
NPC1 O15118 4/20 0.48
POLB P06746 2/20 0.48
PABPC1 P11940 1/20 0.48
GAA P10253 3/20 0.47
MAPT P10636 3/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7239286 1.00 ALOX15 (0.58) ALOX15HTTPLK1DOT1LALDH1A1
SCHEMBL7239395 0.81 ALOX15 (0.54) ALOX15HTTPLK1DOT1LALDH1A1
SCHEMBL7239400 0.81 ALOX15 (0.54) ALOX15HTTPLK1DOT1LALDH1A1
SCHEMBL29924709 0.81 ALOX15 (0.69) ALOX15HTTPLK1DOT1LALDH1A1
SCHEMBL359531 0.81 ALOX15 (0.69) ALOX15HTTPLK1DOT1LALDH1A1
SCHEMBL3095823 0.81 MGAM (0.64) SMN1; SMN2CYP3A4BCAT1RAB9ANPC1
SCHEMBL3095816 0.81 MGAM (0.64) SMN1; SMN2CYP3A4BCAT1RAB9ANPC1
SCHEMBL3095833 0.81 MGAM (0.64) SMN1; SMN2CYP3A4BCAT1RAB9ANPC1
Hydrochloric Acid SCHEMBL6784466 0.79 MGAM (0.62) SMN1; SMN2CYP3A4BCAT1RAB9ANPC1
SCHEMBL323178 0.79 HTT (0.66) ALOX15HTTPLK1DOT1LALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6660764-B2 Telomerase inhibitors such as trans-3-(benzothien-6-yl)-but-2-enoic acid-N-(2-carboxy-phenyl)-amide; use as antitumor agent BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-12-09 US disclosed
US-20020123509-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and the preparation thereof BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-09-05 US disclosed
WO-2002051830-A1 CARBOXAMIDES FOR USE AS TELOMERASE INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020123509-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and the preparation thereof ASS1, ADCY1, ADCY3 ALOX15 1669/4885HTT 3942/4885PLK1 3897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.